Who Paid My Doc
William Nordt
Sports Medicine Richmond, VA Medical Doctor
NPI 1780694760 CMS profile 35560
7650 E Parham Rd, Suite 100, Richmond, VA 23294
General payments
$2,566,190
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$27,253
Through program year 2025, William Nordt of Richmond, VA is reported in the CMS Open Payments database as having received $2,566,190 across 129 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $27,253 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $448,655 | 14 | |
| 2024 | General | $305,479 | 12 | |
| 2023 | General | $381,080 | 14 | |
| 2022 | General | $336,557 | 12 | |
| 2021 | General | $370,456 | 23 | |
| 2020 | General | $350,870 | 18 | |
| 2019 | General | $373,093 | 36 |
Beside peers
- William Nordt
- Sports Medicine median
- Middle half of Sports Medicine
- National median
In program year 2025, general payments to William Nordt were reported at $448,655. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.
Show as a table
| Year | William Nordt | Sports Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $373,093 | $1,176 | $199–$4,249 | $163 |
| 2020 | $350,870 | $708 | $96–$2,890 | $114 |
| 2021 | $370,456 | $1,213 | $152–$3,994 | $132 |
| 2022 | $336,557 | $1,230 | $159–$3,998 | $149 |
| 2023 | $381,080 | $584 | $146–$2,836 | $160 |
| 2024 | $305,479 | $628 | $163–$3,168 | $164 |
| 2025 | $448,655 | $664 | $172–$3,055 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 14 drugsPart D claims
1,653
Drug cost
$5,874
Branded share of claims
1.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Meloxicam | Generic | 849 | $1,578 | |
| Diclofenac Sodium | Generic | 89 | $954 | |
| Methylprednisolone | Generic | 121 | $679 | |
| Celecoxib | Generic | 55 | $503 | |
| Oxycodone Hcl | Generic | 108 | $470 | |
| Cefadroxil | Generic | 56 | $318 | |
| Tramadol Hcl | Generic | 80 | $272 | |
| Amoxicillin | Generic | 144 | $248 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 31 | $228 | |
| Clindamycin Hcl | Generic | 47 | $210 |
The 10 drugs with the highest cost, of 14 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 74 billing codesPaid by Medicare
$492,259
Medicare patients
920
Services billed
19,231
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| Arthritis | 75% | |
| High blood pressure | 70% | |
| Diabetes | 22% | |
| Ischemic heart disease | 22% | |
| Depression | 18% | |
| Osteoporosis | 18% | |
| Cancer | 17% | |
| Atrial fibrillation | 15% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 | Office | 101 | 132 | $68,996 |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 | Office | 154 | 14,040 | $68,587 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 193 | 526 | $2,423 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 212 | 1,096 | $837 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
129 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Sports Medicine in Virginia
David Diduch
Sports Medicine · Charlottesville, VA
Thorp Davis
Sports Medicine · Mechanicsville, VA
Stephen Brockmeier
Sports Medicine · Charlottesville, VA
Justin Griffin
Sports Medicine · Virginia Beach, VA
Brian Werner
Sports Medicine · Charlottesville, VA
Kevin Bonner
Sports Medicine · Virginia Beach, VA
Related records
Sports Medicine in Virginia
Practitioners in the same specialty and state, ranked by reported value.
All Sports Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Virginia
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.